查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1485285

口腔黏膜药物市场 - 按产品类型（片剂、薄膜、液体和喷雾剂）、给药途径、适应症（鸦片类药物依赖性、噁心和呕吐、勃起功能障碍、神经系统疾病）、配销通路和预测，2024 - 2032

Oral Transmucosal Drugs Market - By Product Type (Tablet, Film, Liquid & Spray), Route of Administration, Indication (Opioid Dependence, Nausea & Vomiting, Erectile Dysfunction, Neurological Disorders), Distribution Channel & Forecast, 2024 - 2032
出版日期: | 出版商: Global Market Insights Inc. | 英文 180 Pages | 商品交期: 2-3个工作天内

价格
简介目录

由于该领域的研究和开发迅速发展，2024 年至 2032 年间，全球口腔黏膜药物市场规模的复合年增长率将达到 6.7%。这种激增可归因于对新型药物输送方法的持续探索以及对非侵入性给药途径的日益偏好。例如，2023 年 1 月，马尔默大学的一组研究人员声称，他们有信心透过口腔黏膜的捷径创造出理想的偏头痛治疗方法。在名为「依来曲坦口腔黏膜递送治疗神经系统疾病」的计画中，Sabrina Valetti 和她的研究人员同事选择关注依来曲普坦氢溴酸盐(EB)，该药物因其对曲坦类药物中心臟健康的影响最小而闻名。他们的研究探讨了透过口腔黏膜施用依来曲坦作为治疗手段的潜力。

研究人员正在深入研究可提高生物利用度和快速起效的创新配方。此外，口腔黏膜药物治疗应用的扩展，从疼痛管理到荷尔蒙疗法，正在推动市场成长。此外，黏膜黏附贴片和舌下喷雾剂等技术的进步正在推动患者和医疗保健提供者越来越多地采用该技术。随着研究工作的加强，口腔黏膜药物市场有望大幅扩张，以满足现代医疗保健不断变化的需求。

整个口腔黏膜药物产业根据产品类型、给药途径、适应症、配销通路和地区进行分类。

到 2032 年，薄膜细分市场将出现显着成长。随着製剂技术的进步，跨黏膜薄膜可直接透过口腔黏膜有效输送药物，绕过胃肠道并确保快速起效。此外，它们的易用性和便携性使其对不同人群的患者都有吸引力。因此，由于人们越来越喜欢薄膜作为一种方便有效的剂型，口腔黏膜药物的市场不断扩大。

从2023年到2032年，颊黏膜领域的口腔黏膜药物市场份额将显着扩大。此途径也提高了患者的依从性和便利性，因为它消除了吞嚥药丸或註射的需要。随着製药公司越来越多地投资开发针对口腔递送的创新製剂，口腔黏膜药物的市场不断扩大，这是由于口腔黏膜作为有效药物吸收和递送的有前途途径的潜力所驱动。

在医疗保健支出增加、慢性病盛行率上升以及老年人口不断增长的推动下，欧洲遮阳帆市场从 2024 年到 2032 年将呈现出值得称讚的复合年增长率。此外，有利的政府措施和报销政策进一步刺激市场成长。欧洲消费者越来越青睐非侵入性给药方法，例如口腔黏膜製剂，因为它们方便且有效。此外，该地区正在进行的研究和开发工作不断推出创新产品并扩大治疗应用。因此，欧洲的口腔黏膜药物市场在可预见的未来将持续扩张。

目录

第 1 章：方法与范围

第 2 章：执行摘要

第 3 章：产业洞察

  • 产业生态系统分析
  • 产业影响力
    • 成长动力
      • 口腔黏膜药物的需求不断增长
      • 药物传输技术的进步
      • 慢性病盛行率增加
    • 产业陷阱与挑战
      • 药品审批和商业化的严格监管要求
      • 与研发活动相关的高成本
  • 成长潜力分析
  • 监管环境
  • 技术景观
  • 波特的分析
  • PESTEL分析
  • 技术景观
  • 未来市场趋势

第 4 章：竞争格局

  • 介绍
  • 公司矩阵分析
  • 公司市占率分析
  • 竞争定位矩阵
  • 战略仪表板

第 5 章：市场估计与预测：按产品类型，2018 年 - 2032 年

  • 主要趋势
  • 平板电脑
  • 电影
  • 液体和喷雾
  • 其他产品类型

第 6 章：市场估计与预测：按管理途径，2018 年 - 2032 年

  • 主要趋势
  • 舌下黏膜
  • 颊粘膜
  • 其他给药途径

第 7 章：市场估计与预测：按指标划分，2018 年 - 2032 年

  • 主要趋势
  • 阿片类药物依赖
  • 噁心和呕吐
  • 性功能障碍
  • 神经系统疾病
  • 其他适应症

第 8 章：市场估计与预测：按配销通路，2018 年 - 2032 年

  • 主要趋势
  • 医院药房
  • 零售药局
  • 网路药局

第 9 章：市场估计与预测：按地区划分，2018 年 - 2032 年

  • 主要趋势
  • 北美洲
    • 我们
    • 加拿大
  • 欧洲
    • 德国
    • 英国
    • 法国
    • 义大利
    • 西班牙
    • 欧洲其他地区
  • 亚太地区
    • 中国
    • 日本
    • 印度
    • 澳洲
    • 韩国
    • 亚太地区其他地区
  • 拉丁美洲
    • 巴西
    • 墨西哥
    • 阿根廷
    • 拉丁美洲其他地区
  • 中东和非洲
    • 南非
    • 沙乌地阿拉伯
    • 阿联酋
    • 中东和非洲其他地区

第 10 章：公司简介

  • Aquestive Therapeutics, Inc.
  • C.L.Pharm Co., Ltd.
  • CURE Pharmaceutical
  • IntelGenx Corp
  • Jazz Pharmaceuticals
  • NAL Pharma
  • Novartis AG
  • Pfizer Inc.
  • Teva Pharmaceutical Industries Ltd.
  • ZIM Laboratories Limited.
简介目录
Product Code: 8477

Global Oral Transmucosal Drugs Market Size will witness 6.7% CAGR between 2024 and 2032 due to the burgeoning research and development in the field. This surge can be attributed to the continuous exploration of novel drug delivery methods and the growing preference for non-invasive routes of administration. For instance, in January 2023, a team of researchers at Malmo University claimed that they were confident in their ability to create an ideal migraine treatment through a shortcut in the oral mucous membrane. In their project titled "Oral Transmucosal Delivery of Eletriptan for Neurological Diseases," Sabrina Valetti and her fellow researchers opted to focus on eletriptan hydrobromide (EB), known for its minimal impact on cardiac health among triptans. Their study explored the potential of administering eletriptan via the oral mucosa as a means of treatment.

Researchers are delving into innovative formulations that offer enhanced bioavailability and rapid onset of action. Additionally, the expansion of therapeutic applications for oral transmucosal drugs, ranging from pain management to hormonal therapies, is propelling market growth. Moreover, advancements in technology, such as mucoadhesive patches and sublingual sprays, are driving increased adoption among patients and healthcare providers alike. As research efforts intensify, the Oral Transmucosal Drugs Market is poised for significant expansion, catering to the evolving needs of modern healthcare.

The overall Oral Transmucosal Drugs Industry is classified based on the product type, route of administration, indication, distribution channel, and region.

The films segment will register a significant growth rate by 2032. These thin, dissolvable strips offer a convenient and discreet alternative to traditional routes of drug administration. With advancements in formulation technology, transmucosal films provide efficient drug delivery directly through the oral mucosa, bypassing the gastrointestinal tract and ensuring rapid onset of action. Moreover, their ease of use and portability make them appealing to patients across various demographics. As a result, the market for oral transmucosal drugs continues to expand, driven by the growing preference for films as a convenient and effective dosage form.

The oral transmucosal drugs market share from the buccal mucosa segment will expand appreciably from 2023 to 2032. Buccal administration offers direct access to the bloodstream, bypassing the gastrointestinal tract and liver metabolism, leading to improved bioavailability and faster onset of action. This route also enhances patient compliance and convenience, as it eliminates the need for swallowing pills or injections. With pharmaceutical companies increasingly investing in developing innovative formulations tailored for buccal delivery, the market for oral transmucosal drugs continues to expand, driven by the potential of buccal mucosa as a promising route for efficient drug absorption and delivery.

Europe shade sails market will showcase a commendable CAGR from 2024 to 2032, driven by increasing healthcare expenditures, rising prevalence of chronic diseases, and a growing geriatric population. Additionally, favorable government initiatives and reimbursement policies further stimulate market growth. European consumers increasingly favor non-invasive drug delivery methods, such as oral transmucosal formulations due to their convenience and effectiveness. Moreover, ongoing research and development efforts in the region continue to introduce innovative products and expand therapeutic applications. As a result, the Oral Transmucosal Drugs Market in Europe is poised for continued expansion in the foreseeable future.

Table of Contents

Chapter 1 Methodology & Scope

  • 1.1 Market scope & definitions
  • 1.2 Base estimates & calculations
  • 1.3 Data collection
  • 1.4 Forecast parameters
  • 1.5 Data validation
  • 1.6 Data sources
    • 1.6.1 Primary
    • 1.6.2 Secondary
      • 1.6.2.1 Paid sources
      • 1.6.2.2 Public sources

Chapter 2 Executive Summary

  • 2.1 Industry 360 degree synopsis

Chapter 3 Industry Insights

  • 3.1 Industry ecosystem analysis
  • 3.2 Industry impact forces
    • 3.2.1 Growth drivers
      • 3.2.1.1 Rising demand for oral transmucosal drugs
      • 3.2.1.2 Advancements in drug delivery technologies
      • 3.2.1.3 Increasing prevalence of chronic diseases
    • 3.2.2 Industry pitfalls & challenges
      • 3.2.2.1 Stringent regulatory requirements for drug approval and commercialization
      • 3.2.2.2 High cost associated with research and development activities
  • 3.3 Growth potential analysis
  • 3.4 Regulatory landscape
  • 3.5 Technological landscape
  • 3.6 Porter's analysis
    • 3.6.1 Supplier power
    • 3.6.2 Buyer power
    • 3.6.3 Threat of new entrants
    • 3.6.4 Threat of substitutes
    • 3.6.5 Industry rivalry
  • 3.7 PESTEL analysis
  • 3.8 Technological landscape
  • 3.9 Future market trends

Chapter 4 Competitive Landscape, 2023

  • 4.1 Introduction
  • 4.2 Company matrix analysis
  • 4.3 Company market share analysis
  • 4.4 Competitive positioning matrix
  • 4.5 Strategy dashboard

Chapter 5 Market Estimates and Forecast, By Product Type, 2018 - 2032 ($ Mn)

  • 5.1 Key trends
  • 5.2 Tablets
  • 5.3 Films
  • 5.4 Liquid & spray
  • 5.5 Other product types

Chapter 6 Market Estimates and Forecast, By Route of Administration, 2018 - 2032 ($ Mn)

  • 6.1 Key trends
  • 6.2 Sublingual mucosa
  • 6.3 Buccal mucosa
  • 6.4 Other routes of administration

Chapter 7 Market Estimates and Forecast, By Indication, 2018 - 2032 ($ Mn)

  • 7.1 Key trends
  • 7.2 Opioid dependence
  • 7.3 Nausea and vomiting
  • 7.4 Erectile dysfunction
  • 7.5 Neurological disorders
  • 7.6 Other indications

Chapter 8 Market Estimates and Forecast, By Distribution Channel, 2018 - 2032 ($ Mn)

  • 8.1 Key trends
  • 8.2 Hospital pharmacies
  • 8.3 Retail pharmacies
  • 8.4 Online pharmacies

Chapter 9 Market Estimates and Forecast, By Region, 2018 - 2032 ($ Mn)

  • 9.1 Key trends
  • 9.2 North America
    • 9.2.1 U.S.
    • 9.2.2 Canada
  • 9.3 Europe
    • 9.3.1 Germany
    • 9.3.2 UK
    • 9.3.3 France
    • 9.3.4 Italy
    • 9.3.5 Spain
    • 9.3.6 Rest of Europe
  • 9.4 Asia Pacific
    • 9.4.1 China
    • 9.4.2 Japan
    • 9.4.3 India
    • 9.4.4 Australia
    • 9.4.5 South Korea
    • 9.4.6 Rest of Asia Pacific
  • 9.5 Latin America
    • 9.5.1 Brazil
    • 9.5.2 Mexico
    • 9.5.3 Argentina
    • 9.5.4 Rest of Latin America
  • 9.6 Middle East and Africa
    • 9.6.1 South Africa
    • 9.6.2 Saudi Arabia
    • 9.6.3 UAE
    • 9.6.4 Rest of Middle East and Africa

Chapter 10 Company Profiles

  • 10.1 Aquestive Therapeutics, Inc.
  • 10.2 C.L.Pharm Co., Ltd.
  • 10.3 CURE Pharmaceutical
  • 10.4 IntelGenx Corp
  • 10.5 Jazz Pharmaceuticals
  • 10.6 NAL Pharma
  • 10.7 Novartis AG
  • 10.8 Pfizer Inc.
  • 10.9 Teva Pharmaceutical Industries Ltd.
  • 10.10 ZIM Laboratories Limited.